• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Fight Aging! Newsletter, May 2nd 2022
In this study, we tested the therapeutic potential of VHHASC and a newly generated VHH against murine ASC (VHHmASC) to target ASC specks in vitro and in vivo. We show that pre-incubation of extracellular ASC specks with VHHASC abrogated their inflammatory functions in vitro. Recombinant VHHASC rapidly disassembled pre-formed ASC specks and thus inhibited their ability to seed the nucleation of soluble ASC. Notably, VHHASC required prior cytosolic access to prevent inflammasome activation within cells, but it was effective against extracellular ASC specks released following caspase-1-dependent loss of membrane integrity, an...
Source: Fight Aging! - May 1, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Morning Chronotype Decreases the Risk of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer
CONCLUSION: Our results suggest that the morning chronotype is a protective factor against the development of CIPN in patients with breast cancer who were treated with docetaxel.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01887925.PMID:35132840 | DOI:10.3346/jkms.2022.37.e34
Source: J Korean Med Sci - February 8, 2022 Category: General Medicine Authors: Kyung-Lak Son Dooyoung Jung Kwang-Min Lee Chan-Woo Yeom Gyu Han Oh Tae-Yong Kim Seock-Ah Im Kyung-Hun Lee David Spiegel Bong-Jin Hahm Source Type: research

Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark
CONCLUSIONS: Low SEP in premenopausal women with non-metastatic breast cancer was associated with increased mortality, but not always recurrence. This suggests underdetection of recurrences in certain groups. Poor prognosis in women with low SEP, especially single women, may partly be explained by tamoxifen adherence.PMID:34587961 | DOI:10.1186/s12916-021-02108-z
Source: Clinical Genitourinary Cancer - September 30, 2021 Category: Cancer & Oncology Authors: Cathrine Fonnesbech Hjorth Per Damkier Bent Ejlertsen Timothy Lash Henrik Toft S ørensen Deirdre Cronin-Fenton Source Type: research

Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203)
Tohoku J Exp Med. 2021;254(1):49-55. doi: 10.1620/tjem.254.49.ABSTRACTWhether trastuzumab use beyond disease progression is beneficial in second-line treatment for patients with unresectable human epidermal growth factor receptor 2 (HER2)-positive gastric cancer remains to be elucidated. We conducted this phase II study to assess whether trastuzumab plus docetaxel was effective for patients with previously treated advanced HER2-positive gastric cancer. This trial was a single-arm, open-label, multicenter, phase II study, conducted by Tohoku Clinical Oncology Research and Education Society (T-CORE). Patients aged 20 years o...
Source: The Tohoku Journal of Experimental Medicine - May 31, 2021 Category: Research Authors: Masanobu Takahashi Yasuhiro Sakamoto Kazunori Otsuka Mariko Kanbe Hisatsugu Ohori Yoshiaki Shindo Hiroshi Honda Ken Saijo Kota Ouchi Yasuko Murakawa Hidekazu Takahashi Sadayuki Kawai Yuichi Tanaka Takuhiro Yamaguchi Hideki Shimodaira Takashi Yoshioka Chik Source Type: research

Basket Trials for Intractable Cancer
This study has made a significant impact on clinical practice in cancer patients harboring the TRK translocation, and also illustrates the potential for future advancements in drug development and clinical trials of cancers harboring rare genomic alterations (50). Second, a basket trial may allow screening for potential efficacy across multiple tumor types in order to guide more traditional, disease-specific, follow-up studies. The goal of some basket trials is to obtain an overall assessment of the drug with pooled histologies; in such trials, subsequent analyses are straightforward, and are comparable to those in standa...
Source: Frontiers in Oncology - April 11, 2019 Category: Cancer & Oncology Source Type: research

Understanding the role of new systemic agents in the treatment of prostate cancer
ConclusionThe increasing number of high‐quality clinical trials, with overlapping patient populations has made defining the correct therapy for men with mPC challenging for urologists and medical oncologists. The data suggests that the optimal sequence of drugs is not only unknown but also not necessarily the same for each patient. As such, we suggest a more individualized approach to the treatment of prostate cancer depending on patient and disease factors.
Source: BJU International - October 5, 2016 Category: Urology & Nephrology Authors: Julia Corfield, Jack Crozier, Anthony Joshua, Damien Bolton, Nathan Lawrentschuck Tags: Supplement Article Source Type: research